Biweekly oxaliplatin combined with oral capecitabine (OXXEL regimen) as first-line treatment of metastatic colorectal cancer patients: A Southern Italy Cooperative Oncology Group phase II study

Cancer Chemotherapy and Pharmacology

Volumn 56, Issue 5, 2005, Pages 481-486

  Comella, P ^a   Massidda, B ^b   Palmeri, S ^c   Farris, A ^d   Lucia, L De ^e   Natale, D ^f   Maiorino, L ^g   Tafuto, S ^h   Cataldis, G De ⁱ   Casaretti, R ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF CAGLIARI   (Italy)

^c UNIVERSITY OF PALERMO   (Italy)

^d Università Degli Studi di Sabari   (Italy)

^e City Hospital   (Italy)

^f San Massimo Hospital   (Italy)

^g San Gennaro Hospital   (Italy)

^h Santa Maria Hospital   (Italy)

ⁱ Ospedale G da Procida   (Italy)

Author keywords

Biweekly treatment; Capecitabine; Metastatic colorectal cancer; Oxaliplatin; OXXEL regimen

Indexed keywords

CAPECITABINE; OXALIPLATIN;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; FUNCTIONAL DISEASE; GASTROINTESTINAL TOXICITY; HAIR LOSS; HUMAN; ITALY; LIVER TOXICITY; MALE; METASTASIS; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN TOXICITY; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING; WEIGHT REDUCTION;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; ITALY; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PERITONEAL NEOPLASMS;

EID: 27644511668     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-005-1003-6     Document Type: Article

References (19)

1. Borner MM, Dietrich D, Stupp R et al (2002) Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer. J Clin Oncol 20:1759-1766
2. Cassidy J, Tabernero J, Twelves C, et al (2004) XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Onc 22:2084-2091
3. Comella P, Massidda B, Filippelli G, et al (2004) Oxaliplatin (OXA) plus levo-folinic acid (1-FA) and 5-fluorouacil (FU) i.v. bolus (OXAFAFU) is more active than irinotecan (IRI) plus levo-folinic acid (1-FA) and 5-fluorouacil (FU) i.v. bolus (IR-IFAFU) in advanced colorectal carcinoma (ACC): Final results of the Southern Italy Cooperative Oncology Group (SICOG) trial 0103. Ann Oncol 15 (Supplement 3): iii72, abstract# 271PD
4. Cox DR (1970) The analysis of binary data. Methnem, London
5. De Gramont A, Cervantes A, André T et al (2004) OPTIMOX study: FOLFOX7/LV5FU2 compared to FOLFOX4 in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 251s, abstract# 3525
6. Fisher GA, Kuo T, Cho CD et al (2004) A phase II study of Gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 248s, abstract# 3514
7. Goldberg RM, Sargent DJ, Morton RF et al (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23-30
8. Grothey A, Jordan K, Kellner O et al (2003) Capecitabine plus irinotecan (CAPIRI) vs capecitabine plus oxaliplatin (CAPOX) as first-line therapy of advanced colorectal cancer (ACRC): updated results of a randomized phase II trial. Eur J Cancer S90, abstract# 295
9. Hoff PM, Ansari R. Batisti G et al (2001) Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 19:2282-2292
10. Kaplan EL, Meier P (1958) Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481
11. Maindrault-Gœbel F, de Gramont A, Louvet C et al (2000) Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR). Ann Oncol 11:1477-1483
12. Maindrault-Gœbel F, de Gramont A, Louvet C et al (2001) High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7). Eur J Cancer 37:1000-1005
13. Miller AB, Hoogstraten B, Staquet M, Winkler V (1981) Reporting results of cancer treatment. Cancer 47:207-214
14. Scheithauer WS, Kornek GV, Raderer M, et al (2003) Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 21:1307-1312
15. Simon R (1989) Optimal two stage design for phase II clinical trials. Contr Clin Trial 10:1-10
16. Tabernero JM, Van Cutsem E, Sastre J et al (2004) An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLOFOX-4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing Epidermal Growth Factor Receptor (EGFR): Preliminary results. Proc Am Soc Clin Oncol 248s, abstract# 3512
17. Twelves C, on behalf of the Xeloda Colorectal Cancer Group (2002) Capecitabine as first-line treatment in colorectal cancer: pooled data from two large, phase III trials. Eur J Cancer 38:S15-S20
18. Van Cutsem E, Twelves C, Cassidy J et al (2001) Oral capecitabine compared with intravenous 5-fluorouracil plus leucovorin (Mayo Clinic regimen) in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 19:4097-4106
19. Zeuli M, Nardoni C, Pino MS et al (2003) Phase II study of capecitabine and oxaliplatin as first-line treatment in advanced colorectal cancer. Ann Oncol 14:1378-1382